Compare MOH & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MOH | CYTK |
|---|---|---|
| Founded | 1980 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.5B | 10.7B |
| IPO Year | 2002 | 2004 |
| Metric | MOH | CYTK |
|---|---|---|
| Price | $206.28 | $62.30 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 19 | 23 |
| Target Price | ★ $209.12 | $109.40 |
| AVG Volume (30 Days) | 603.2K | ★ 2.0M |
| Earning Date | 10-21-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.46 | N/A |
| Revenue | ★ $45,426,000,000.00 | $13,368,000.00 |
| Revenue This Year | $2.05 | $72.63 |
| Revenue Next Year | $8.06 | $181.06 |
| P/E Ratio | $145.83 | ★ N/A |
| Revenue Growth | ★ 11.75 | N/A |
| 52 Week Low | $121.06 | $54.30 |
| 52 Week High | $244.89 | $88.31 |
| Indicator | MOH | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 58.17 | 36.80 |
| Support Level | $188.03 | $59.21 |
| Resistance Level | $214.60 | $67.65 |
| Average True Range (ATR) | 7.62 | 2.01 |
| MACD | 2.39 | 0.31 |
| Stochastic Oscillator | 73.74 | 34.67 |
Molina Healthcare Inc provides medical insurance plans through Medicaid, the individual exchanges, and Medicare. The company operates in four reportable segments consisting of: 1) Medicaid; 2) Medicare; 3) Marketplace; and 4) Other. It manages health benefit risks for more than 5 million people, with more than 85% of those members coming through contracts with state governments for their Medicaid programs. Medicaid contracts in four states-California, New York, Texas, and Washington-account for over half of its enrollees.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.